

10/075,918

- 3 -


Barvian et al.

AMENDMENT TO THE CLAIMS

The following listing of claim(s) will replace all prior versions, and listings, of claim(s) in the application.

Listing of claim(s):

Claim 1 (amended). A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula I



I

wherein:

R^1 , R^2 , and R^3 independently are hydrogen, halo, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, NO_2 , NR^4R^5 , CN, or CF_3 ;

E is independently O or S;

A and B independently are OR^4 or NR^4R^5 ;

each R^4 and R^5 independently are H, ~~C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $(CH_2)_n$ -aryl, $(CH_2)_n$ -cycloalkyl, $(CH_2)_n$ -heterocyclyl,~~
 $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

10/075,918

- 4 -

Barvian et al.


n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof;

wherein the compound isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl)
ester is excluded.

Claim 2 (amended).

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula II



wherein:

R¹, R², and R³ independently are hydrogen, halo, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, NO₂, NR⁴R⁵, CN, or CF₃; and

R⁴ and R⁵ is independently H, ~~C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, (CH₂)_n aryl, (CH₂)_n cycloalkyl, or (CH₂)_n heterocyclyl,~~ (CH₂)_n heteroaryl, or R⁴ and R⁵ when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof;

wherein the compound isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl)
ester is excluded.


10/075,918

- 5 -

Barvian et al.

Claim 3 (amended).

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula III



III

wherein:

R^1 , R^2 , and R^3 independently are hydrogen, halo, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, NO_2 , NR^4R^5 , CN, or CF_3 ;

R^4 and R^5 independently are H, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $(CH_2)_n$ aryl, $(CH_2)_n$ cycloalkyl, $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.


Claim 4 (canceled).**Claim 5 (amended).**

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula V

10/075,918

- 6 -

Barvian et al.



wherein:

R^1 , R^2 , and R^3 independently are hydrogen, halo, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, NO_2 , NR^4R^5 , CN, or CF_3 , and Het is an unsubstituted or substituted heteroaryl group;

R^4 and R^5 independently are H, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $(CH_2)_n$ aryl, $(CH_2)_n$ cycloalkyl, $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;


n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof;

wherein the compound isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl) ester is excluded.

Claim 6 (amended).

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula VI



or a pharmaceutically acceptable salt thereof,

10/075,918

- 7 -

Barvian et al.

wherein:

R¹, R², and R³ independently are hydrogen, halo, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, NO₂, NR⁴R⁵, CN, or CF₃;

R⁴ and R⁵ independently are H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, (CH₂)_n-aryl, (CH₂)_n-cycloalkyl, (CH₂)_n-heterocyclyl, (CH₂)_n-heteroaryl, or R⁴ and R⁵ when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; and n is an integer from 0 to 6.

Claim 7 (amended). A compound selected from:

4-Methoxy-N,N'-bis(4-methoxybenzyl)-isophthalamide;
 Isophthalic acid di-(2,1,3-benzothiadiazol-5-yl) methyl ester;
~~4-Methoxy-isophthalic acid dibenzyl ester;~~
 4-Methoxy-isophthalic acid dipyridin-4-ylmethyl ester;
~~Isophthalic acid bis-(4-fluoro-benzyl)-ester;~~
~~Isophthalic acid bis-(3-fluoro-benzyl)-ester;~~
~~Isophthalic acid bis-(4-methoxy-benzyl)-ester;~~
~~Isophthalic acid bis-(3-methoxy-benzyl)-ester;~~
~~Isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl)-ester;~~
 N,N'-Bis-(3-fluoro-benzyl)-isophthalamide;
~~4-Acetyl-isophthalic acid dibenzyl ester;~~
~~4-Methoxycarbonylmethoxy-isophthalic acid dibenzyl ester;~~
 N,N'-Bis-1,3-benzodioxol-5-ylmethyl-4-methoxy-isophthalamide;
~~N-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N'-(4-methoxy-benzyl)-isophthalamide;~~
 4-Methoxy-N,N'-bis(4-methoxybenzyl)-isophthalamide;

10/075,918

- 8 -

Barvian et al.

~~N-1,3-Benzodioxol-5-ylmethyl N'-(4-chloro-benzyl)-4-methoxy-~~
~~isophthalamide;~~

~~N-Benzyl-4-methoxy-N'-(4-methoxy-benzyl)-isophthalamide;~~

~~N'-Benzyl-4-methoxy-N-(4-methoxy-benzyl)-isophthalamide;~~

~~4-Methoxy-N-(4-methoxy-benzyl)-N'-pyridin-4-ylmethyl-isophthalamide;~~

~~N'-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N-(2-phenoxy-ethyl)-~~
~~isophthalamide;~~

~~N-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N'-(2-phenoxy-ethyl)-~~
~~isophthalamide;~~

~~N-1,3-Benzodioxol-5-ylmethyl-N'-furan-2-ylmethyl-isophthalamide;~~

~~N'-1,3-Benzodioxol-5-ylmethyl-N-(2-ethoxy-ethyl)-4-methoxy-~~
~~isophthalamide;~~

~~N,N'-Bis-(3-hydroxymethyl-phenyl)-isophthalamide;~~

~~N-Benzyl-4-methoxy-N'-(2-phenoxy-ethyl)-isophthalamide;~~

~~4-Methoxy-N,N'-bis-(4-methyl-benzyl)-isophthalamide;~~

~~4-Methoxy-N,N'-bis-(3-methoxy-benzyl)-isophthalamide;~~

~~N-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N'-(4-methoxy-benzyl)-~~
~~isophthalamide;~~

~~N-1,3-Benzodioxol-5-ylmethyl-isophthalamide-acid;~~
~~(4-carboxyphenyl)methyl-ester;~~

~~4-[[3-(3-Methoxy-benzylcarbamoyl)-benzoylamino]methyl]-benzoic~~
~~acid;~~

~~4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester;~~

~~4-[[3-(3-Methoxy-benzylcarbamoyl)-benzoylamino]methyl]-benzoic~~
~~acid-methyl ester;~~

~~N-(3-Methoxy-benzyl)-N'-(4-nitro-benzyl)-isophthalamide;~~

~~N-(3,4-Dichloro-benzyl)-N'-pyridin-4-ylmethyl-isophthalamide;~~

~~N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;~~

~~N-(4-Chloro-benzyl)-N'-(3-methoxy-benzyl)-isophthalamide;~~

10/075,918

- 9 -

Barvian et al.

~~N-(3,4-Dichloro-benzyl)-N'-(3-methoxy-benzyl)-isophthalamide;~~
~~N-(4-Methoxy-benzyl)-N'-(3-methoxy-benzyl)-isophthalamide;~~
~~N,N'-Bis-(4-fluoro-3-methoxy-benzyl)-isophthalamide;~~
~~4-Ethoxy-N1,N3-bis-(3-methoxy-benzyl)-isophthalamide;~~
~~N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;~~
~~N-(3-Methoxy-benzyl)-N'-pyridin-3-ylmethyl-isophthalamide;~~
~~N-(3-Methoxy-benzyl)-N'-pyridin-4-ylmethyl-isophthalamide;~~
~~N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;~~
~~N-(3-Methoxy-benzyl)-N'-(3-trifluoromethoxy-benzyl)-isophthalamide;~~
~~N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;~~
~~4-Isopropoxy-N1,N3-bis-(3-methoxy-benzyl)-isophthalamide;~~
~~N1-Benzyl-4-methoxy-N3-(4-methoxy-benzyl)-isophthalamide;~~
~~N1-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N3-(4-methoxy-benzyl)-~~
~~isophthalamide;~~
~~N1-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N3-(2-phenoxy-ethyl)-~~
~~isophthalamide;~~
~~N1-Benzyl-4-methoxy-N3-(2-phenoxy-ethyl)-isophthalamide;~~
~~N1-1,3-Benzodioxol-5-ylmethyl-N3-(4-chloro-benzyl)-4-methoxy-~~
~~isophthalamide;~~
~~N3-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N1-(4-methoxy-benzyl)-~~
~~isophthalamide;~~
~~N3-Benzyl-4-methoxy-N1-(4-methoxy-benzyl)-isophthalamide;~~
~~N3-1,3-Benzodioxol-5-ylmethyl-4-methoxy-N1-(2-phenoxy-ethyl)-~~
~~isophthalamide;~~
~~N3-1,3-Benzodioxol-5-ylmethyl-N1-(2-ethoxy-ethyl)-4-methoxy-~~
~~isophthalamide;~~
~~4-Methoxy-N1-(4-methoxy-benzyl)-N3-pyridin-4-ylmethyl-~~
~~isophthalamide;~~
~~4-Amino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;~~
~~4-Acetylamino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;~~

10/075,918

- 10 -

Barvian et al.

~~N (3-Methoxy-benzyl)-N' pyridin-3-ylmethyl-isophthalamide;~~
~~N (3-Methoxy-benzyl)-N' pyridin-4-ylmethyl-isophthalamide;~~
~~N1,1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;~~
~~N (4-Chloro-benzyl)-N' (3-methoxy-benzyl)-isophthalamide;~~
~~N (3,4-Dichloro-benzyl)-N' (3-methoxy-benzyl)-isophthalamide;~~
~~N (4-Methoxy-benzyl)-N' (3-methoxy-benzyl)-isophthalamide;~~
~~N (3-Methoxy-benzyl)-N' (4-methyl-benzyl)-isophthalamide;~~
~~N,N'-Bis (4-fluoro-3-methoxy-benzyl)-isophthalamide;~~
~~((3-[(1,3-Benzodioxol-5-ylmethyl)-carbamoyl]-benzoyl)-benzyl-amino)-acetic acid;~~
~~N-Benzo[1,3]dioxol-5-ylmethyl-isophthalamide(4-hydroxymethyl-benzoic acid)-ester;~~
~~N (3,4-Dichloro-benzyl)-N' pyridin-4-ylmethyl-isophthalamide;~~
~~N (3-Methoxy-benzyl)-N' (4-nitro-benzyl)-isophthalamide;~~
~~4-[[3-(3-Methoxy-benzylcarbamoyl)-benzoylamino]-methyl]-benzoic acid-methyl ester;~~
~~N-3-methoxybenzyl-isophthalamide(4-hydroxymethyl-benzoic acid)-ester;~~
~~4-[[3-(3-Methoxy-benzylcarbamoyl)-benzoylamino]-methyl]-benzoic acid;~~
~~N (3-Amino-benzyl)-N' (3-methoxy-benzyl)-isophthalamide;~~
~~N (3-Methoxy-benzyl)-N' (3-nitro-benzyl)-isophthalamide;~~
~~4-Ethoxy-N'1,N'3-bis (3-methoxy-benzyl)-isophthalamide;~~
~~N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;~~
~~N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-propoxy-isophthalamide;~~
~~N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;~~
~~N1,N3-Bis-2,1,3-benzothiadiazol-5-ylmethyl-4-methoxy-isophthalamide;~~
 and
 4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester.

10/075,918

- 11 -

Barvian et al.

Claim 8 (original). A pharmaceutical composition, comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 9 (original). A pharmaceutical composition for inhibiting MMP-13 in a mammal, comprising an MMP-13 inhibiting amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 10 (amended). A method for inhibiting MMP-13 in an animal, comprising administering to the animal an MMP-13 inhibiting amount of a compound of ~~Formula I~~ Claim 1, or a pharmaceutically acceptable salt thereof.

Claims 11 and 12 (canceled).

Claim 13 (amended). A method for treating breast carcinoma, comprising administering to a patient suffering from such a disease an anticancer effective amount of a compound of ~~Formula I~~ Claim 1, or a pharmaceutically acceptable salt thereof.

Claim 14 (amended). A method for treating a rheumatoid arthritis, comprising administering to a patient suffering from such a disease an effective amount of a compound of ~~Formula I~~ Claim 1, or a pharmaceutically acceptable salt thereof.

Claim 15 (amended). A method for treating a osteoarthritis, comprising administering to a patient suffering from such a disease an effective amount of a compound of ~~Formula I~~ Claim 1, or a pharmaceutically acceptable salt thereof.

10/075,918

- 12 -

Barvian et al.

Claim 16 (amended). A method for treating a heart failure, comprising administering to a patient suffering from such a disease an effective amount of a compound of ~~Formula I~~ Claim 1, or a pharmaceutically acceptable salt thereof.

Claim 17 (amended). A method for treating a inflammation, comprising administering to a patient suffering from such a disease an effective amount of a compound of ~~Formula I~~ Claim 1, or a pharmaceutically acceptable salt thereof.